Menu

Sign in

Sign in

Contact us

Homepage > Company > Media > Pharma News > 2019

Pharma News, 2019

AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patien

AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patien

NORTH CHICAGO, Ill.

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-Cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (AHUS)

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-Cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (AHUS)

BOSTON--(BUSINESS WIRE) -- Jan.

Not-for-profit to offer 20 generic drugs in 2019 to alleviate shortages

Not-for-profit to offer 20 generic drugs in 2019 to alleviate shortages

(Reuters) - A new not-for-profit supplier of generic drugs formed by a consortium of hospitals systems said it expects this year to be able to provide about 20 products to alleviate shortages ...

Harvard researchers report positive trial results with artificial pancreas smartphone app

Harvard researchers report positive trial results with artificial pancreas smartphone app

The results of a new clinical trial have shown the safety and efficacy of the interoperable Artificial Pancreas System smartphone app (iAPS), which can interface wirelessly with leading contin...

Cystic fibrosis drug combo found safe and effective for 2- to 5-year-olds

Cystic fibrosis drug combo found safe and effective for 2- to 5-year-olds

An open label Phase 3 study conducted at Ann & Robert H.

Antimicrobial resistance: UK launches 5-year action plan and 20-year vision

Antimicrobial resistance: UK launches 5-year action plan and 20-year vision

The plans outline the UK's contribution to containing and controlling antimicrobial resistance (AMR) in health, animals, the environment and the food chain.

It Looks Like a Common Vaccine Is Unintentionally Helping Prevent Type 1 Diabetes

It Looks Like a Common Vaccine Is Unintentionally Helping Prevent Type 1 Diabetes

23 JAN 2019Type 1 diabetes has been on the rise worldwide, but in Australia, the problem appears to be turning around at last.

Chinese Scientists Have Cloned a Genetically Altered Primate For The First Time

Chinese Scientists Have Cloned a Genetically Altered Primate For The First Time

This time last year, the first primates cloned through a nucleus transfer technique made headlines around the world.

The Cause of Alzheimer's Could Be Coming From Inside Your Mouth, Study Claims

The Cause of Alzheimer's Could Be Coming From Inside Your Mouth, Study Claims

In recent years, a growing number of scientific studies have backed an alarming hypothesis.

EMA cites Slovakian sterile drugmaker and says its meds should be recalled

EMA cites Slovakian sterile drugmaker and says its meds should be recalled

The European Medicines Agency has taken action against a Slovakian sterile drugmaker after inspectors tallied up nearly two dozen issues.

As drug prices took daily fire last year, PhRMA racked up a record lobbying bill

As drug prices took daily fire last year, PhRMA racked up a record lobbying bill

Between President Trump on Twitter and critics in Congress, pharma and its pricing faced daily fire last year.

Ozempic launched for type II diabetes in the UK

Ozempic launched for type II diabetes in the UK

Novo Nordisk has announced that Ozempic, a new once-weekly GLP-1 (human glucagon-like peptide-1) analogue injection for the treatment of type II diabetes, is now available in the UK.

55 56 57 585960 61 62 63

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote